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French health authorities constantly publish public health
recommendations, and ever since the pay-for-performance
(P4P) programme was implemented in France, physicians have
been more motivated to follow them [1]. Currently, guidelines
regarding pharyngeal infection, one of the most common
community-acquired infections [2], recommend the use of a
Centor clinical scoring system to identify patients with a high
probability of group A streptococcus (GAS) pharyngitis, and
the use of rapid antigen tests (RATs) to confirm the
microbiological diagnosis [3]. Antibiotic therapy is recom-
mended only for patients with microbiological evidence of
GAS, with the aims of reducing the duration and severity of
clinical symptoms and of preventing post-streptococcal com-
plications. The public health objectives of these guidelines are
to avoid inappropriate antibiotic treatments, to minimize the
risk of antibiotic resistance, and to limit pharmaceutical
expenditures. Despite the P4P incentives, there remained
some risk-averse physicians who prescribed more antibiotics
when they did not use RATs than risk-tolerant doctors did [4].
To date, these guidelines are considered to represent the
best practices for pharyngitis. However, upon what evidence
are these recommendations based? What is the strategy of the
risk-averse physicians who did not follow tonsillitis guidelines
and prescribed more antibiotics? Most guidelines recommend
antibiotic treatment in all patients with symptomatic pharyn-
gitis and microbiological evidence of GAS in the pharynx.
However, no antibiotic regimen eradicates GAS from the
pharynx in 100% of treated patients [5], and the antibiotic has
only a modest effect in reducing the symptoms of tonsillitis
[3,6]. Antibiotic therapy is primarily helpful to prevent acute
rheumatic fever; however, this evidence was found only in
trials conducted during the 1950s and 1960s, when the
incidence of rheumatic fever was dramatically higher than it is
now. The incidence of rheumatic fever remains significant in
developing countries, and can reach 80–254 per 100 000 in
indigenous Australian communities [7], but in developed
countries the disease has been almost eradicated and remains
exceptional. Consequently, guidelines for the management of
tonsillitis in Europe have become outdated. In fact, only 32
cases of acute rheumatic fever in children aged 5–14 years
were reported between 1995 and 1997 in France [8]. Among
these cases, 12 of 32 (37.5%) did not present with an episode
of pharyngitis before the diagnosis of rheumatic fever;
therefore, it could not have been prevented with antibiotics.
FIG. 1. Evaluation of the cost of antibiotic treatment of streptococcal tonsillitis to prevent a putative case of acute rheumatic fever in France.
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Moreover, half of these patients diagnosed with tonsillitis
received antibiotics that failed to prevent acute rheumatic
fever. Furthermore, the beneficial effect of antibiotics to
prevent post-streptococcal glomerulonephritis and suppura-
tive complications remains unclear [3]. Finally, it is likely that
the incidence of rheumatic fever in France has declined even
further over the past two decades.
Guidelines have been mainly or exclusively focused on GAS
or related clinical presentations. Throat swab cultures are now
less often performed in favour of RATs, despite the advantage
that culture methods have of identifying other causes of
bacterial pharyngitis. This strategy is harmful, because it
obscures the detection of other aetiological agents responsible
for pharyngitis that now go undetected by routine diagnosis in
clinical microbiology laboratories. In fact, the pathogenic role
of emerging bacteria, such as Fusobacterium necrophorum, has
been demonstrated in recent years. With the use of culture or
quantitative PCR on throat swabs from patients presenting
with acute pharyngitis, F. necrophorum was found with a
prevalence range of 4.9% [9] to 10% [10]. The prevalence
seems to be higher in young adults; Amess et al. reported a
prevalence of 9.7% among patients aged 11–25 years [9], and
Jensen et al. a prevalence of 51% among patients aged 18–
32 years with non-streptococcal tonsillitis [11]. Like GAS,
F. necrophorum can also be carried asymptomatically in the
pharynx, with a prevalence range from 0% to 21% [10,11].
We computed the cost of prevention of a putative case of
rheumatic fever (Fig. 1). Our analysis showed that the total
cost of treatment of pharyngitis in France is €21 960 000,
which brings us to a cost of €2 196 000 per case of rheumatic
fever. Every year, millions of euros are spent to prevent a
disease that no longer exists in France. This cost of preventing
rheumatic fever is very important, because the guideline
recommends treatment with antibiotic therapy for all strep-
tococcal tonsillitis cases.
We believe that a reassessment of the management of acute
pharyngitis is required. Bacterial agents other than GAS may
be responsible for acute sore throat, and should not be
underestimated. We suggest that future recommendations be
based more on the clinical severity and the evolution of the
patient, and focus less on the detection of GAS. Overtreat-
ment of streptococcal pharyngitis leads to inappropriate
antibiotic use, which can be avoided by clinical evaluation of
the need for antibiotic treatment.
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